Methylxanthines such as theophylline and aminophylline have been used for the treatment of asthma since 19221 and currently many preparations are available for oral, rectal, and parenteral administration. The narrow therapeutic index of these drugs and the wide intersubject variations of metabolism have, however, hindered their use as first line treatment for asthma in Europe. Over the last five years the introduction of serum drug concentration monitoring, together with the availability of oral slow release preparations, has led to the increased use of theophylline and related compounds as adjuncts to other forms of asthma treatment. The accepted serum therapeutic range of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Two patients were receiving oral theophylline preparations and these were omitted for 24 hours beforethe study days. All subjects gave informed consent and the study was approved by the Southampton ethical committee. Four xanthine preparations and saline placebo were used in the study. Because of spontaneous fluctuations in the severity of asthma and intercurrent illness not all the subjects were able to receive all four preparations. Micronised theophylline and glycine theophyllinate (both from Riker Laboratories, Loughborough) were dissolved in saline to produce concentrations of 10 mg/ml (pH 5.0) and 50 mg/ml (pH 9.1) respectively. Theophylline ethylenediamine (aminophylline 250 mg/ml, Antigen Ltd, Roscrea, Ireland) was diluted with saline to a concentration of 50 mg/ml (pH 9.4) and diprophylline 125 mg/ml (pH 5.4) was prepared similarly by diluting the commercial solubilised parenteral preparation Silbephylline (250 mg/ml, Berk Pharmaceuticals Ltd, Eastboume). Sodium chloride 0.9% (pH 5.2) was used as placebo control.
The solutions were administered in random order from a volume of 4 ied by less than 15% between study days. All xanthine inhalations had an unpleasant taste. This was most noticeable with the more concentrated aminophylline and diprophylline. Subjects varied in their subjective responses to the inhalations, but coughing during the first minute was frequent with all the xanthines.
All four xanthine preparations produced a significant increase in sGaw by comparison with saline placebo (fig). The response was rapid, reaching a peak within five minutes. The xanthine induced increase in sGaw was short lived, the values not Cushley, Holgate being significantly different from those observed with saline placebo at 30 minutes. In the concentrations given there were no significant differences in the time course-response curves for any of the four xanthines.
Inhalation of 200 ,ug salbutamol from a metered dose inhaler produced an additional increase in sGaw of 135% (24%) after saline placebo, 150% (20%) after theophylline, 160% (27%) after aminophylline, 135% (23%) after diprophylline, and 150% (28%) after glycine theophyllinate. There was no significant difference in the response to salbutamol whether preceded by inhaled saline or any of the xanthine preparations.
Discussion
In this group of patients with moderately severe asthma inhaled theophylline and related xanthines given as a nebulised aerosol produced a rapid but short lived bronchodilatation (fig). The degree of bronchodilatation was small compared with that produced by a conventional dose of inhaled salbutamol (200 ,ug) from a metered dose inhaler. All the xanthines had an unpleasant taste and produced coughing early during the inhalation, particularly the more concentrated preparations aminophylline and diprophylline.
Information on inhaled xanthine derivatives for the treatment of asthma is scant and incomplete. Two early studies89 using inhaled theophylline and aminophylline were encouraging, though the bronchodilatation reported was short lived. In the 1960s two uncontrolled studies reported definite benefit with inhaled aminophylline.'°" A controlled study found aminophylline too irritant to be clinically useful, although one theophylline salt, neuphylline, did produce significant bronchodilatation. ' '5 The studies reported here used various drug concentrations and methods of inhalation.
The present study was designed to investigate the bronchodilator efficacy of maximally tolerated concentrations of four alkyl substituted xanthine prep- arations. The main limitation to dose was the solubility of the compounds and the unpleasant taste and pronounced cough produced by the concentrated preparations. We made no attempt to obtain concentration-response data. With all four xanthine derivatives inhalation produced bronchodilatation Bronchodilator actions of xanthine derivatives administered by inhalation in asthma as reflected by an increase in sGaw, but at best the response was only 49% of that achieved with 200 ,ug inhaled salbutamol. The reason for the low bronchodilator efficacy of inhaled xanthines is at first sight difficult to explain since it has been proposed that these drugs and the 12 adrenoceptor agonists cause bronchodilatation through the same final pathway, by increasing concentrations of cyclic AMP in airway smooth muscle.'6 One explanation may be limited retention of inhaled xanthines in the airways, so that local concentrations are insufficient to produce an optimal bronchodilator effect. Wich oral and intravenous theophylline therapeutic efficacy is closely related to circulating drug concentrations and if serum concentrations are not maintained the airway effects are rapidly lost. In studies of inhaled methylxanthines for asthma serum theophylline concentrations have always been below 5 ,ug/ml and often undetectable.56i5 We did not measure serum concentrations but with the total amount of each drug inhaled concentrations of acccepted therapeutic significance are most unlikely to have been achieved. The very rapid response with the inhaled route implies a local action of xanthines in the airways and the short duration of effect suggests rapid removal of the drug from its site of action.
Our results are in agreement with those of most other studies on inhaled methylxanthines in that the effect produced was very much less than that of a standard dose of inhaled 13 adrenoceptor agoniSt.-613 Furthermore, the relatively small bronchodilator action was offset by the unpleasant taste and irritant properties of the xanthines. We conclude that the xanthine derivatives used in this study when administered by inhalation are unlikely to be of benefit in the treatment of asthma.
